Ashland (ASH) reported a revenue of $386 million for Q1, down 4.7% from last year. The earnings per share (EPS) were $0.26, compared to $0.28 from the same quarter last year. The revenue fell short of the Zacks Consensus Estimate by 5.47%, which expected $408.33 million. However, the EPS surpassed expectations by 12.46%, where the consensus was $0.23. Here’s a breakdown by segment: – **Intermediates**: Revenue was $31 million, slightly above the estimated $30.26 million, despite a 6.1% decline year-over-year. – **Life Sciences**: Generated $139 million, a 3.7% increase, but still below the expected $145.72 million. – **Personal Care**: Revenue hit $123 million, an 8.2% drop from last year, missing the forecast of $131.71 million. – **Specialty Additives**: Revenue came in at $102 million, down 11.3% year-over-year, also below the estimate of $110.58 million. Adjusted EBITDA details are as follows: – **Life Sciences**: $31 million, lower than the expected $32.29 million. – **Personal Care**: $26 million, close to the forecast of $26.78 million. – **Specialty Additives**: $15 million, below expectations. – **Intermediates**: $1 million, also underperforming. – **Unallocated Operating Income**: $-26 million, against a target of $-17.25 million. The main takeaway is the significant revenue miss, which overshadows the small earnings beat. This revenue weakness suggests a lack of demand for Ashland’s products, potentially putting downward pressure on the stock. Consequently, a bearish outlook in the upcoming weeks seems likely. Analyzing the details reveals that the weakness spans multiple business areas, especially Personal Care and Specialty Additives. Both segments not only missed sales targets but also experienced sharp year-over-year declines of 8.2% and 11.3%, respectively. Even Life Sciences, which had growth, still did not meet expectations, highlighting widespread challenges. This report reflects the tough macroeconomic environment we’re facing. In the second half of 2025, global industrial production was slow. Recent data for January 2026 shows the ISM Manufacturing PMI at 49.2, indicating continued contraction in the sector, creating a challenging landscape for specialty chemical companies like Ashland. Given this situation, buying put options on ASH could be a sound strategy. We might consider purchasing puts with expiration dates in March or April 2026 to prepare for a potential stock price decline following these disappointing results. This strategy can allow us to profit from a stock price drop while limiting our maximum risk to the premium paid. Alternatively, if you anticipate the stock will trade sideways or drift lower, selling out-of-the-money call spreads might work well. This approach enables us to collect a premium, believing the stock’s potential upside is limited after this report. A bear call spread limits our risk and can be profitable even if the stock doesn’t move much.

here to set up a live account on VT Markets now